AgeX Therapeutics and its BVI-registered investor Juvenescence Ltd. announced publication of paper on the engineering of universal cells

Juvenescence Ltd., BVI-registered science company developing technologies to treat aging, and AgeX Therapeutics, Inc., a biotechnology company developing therapeutics for human aging and regeneration, announced the publication of a new paper in the scientific journal Regenerative Medicine. The published paper is on the strategies of engineering of allogeneic cells to be hypoimmunogenic (universal), so as not to produce an immune response. Also, the paper presents previously unpublished observation in vivo on allogeneic human stem cells (hPSCs).

The leading author of the paper is Dr. Nafees Malik, Chief Operating Officer at AgeX and Head of Cell & Gene Therapy at Juvenescence, which is a major investor in AgeX. His co-authors on the paper are Gregory Bailey, MD, Chairman of the Board of Directors of AgeX and CEO of Juvenescence; Annalisa Jenkins, MBBS, FRCP, who serves on the Board of Directors of AgeX; and Jim Mellon, Chairman of Juvenescence.

Dr Malik said in his comments on the publication: “This is a huge area of focus for us at AgeX, via our UniverCyte technology platform. In support of our own research and as a service to the overall field, we decided to put together this paper, analyzing all the leading strategies to engineer universal cells and encapsulating them in one paper.”

Comments are closed.